|
|
Post by #NoMoreNeedles on Oct 5, 2017 8:41:00 GMT -5
As per Barron's article written by Maxim
|
|
|
|
Post by novafett on Oct 5, 2017 9:28:34 GMT -5
Link or copy?
|
|
|
|
Post by #NoMoreNeedles on Oct 5, 2017 9:43:59 GMT -5
www.barrons.com/articles/mannkind-victorious-in-label-revision-1507139382MannKind Victorious in Label Revision The FDA approved label claims of Afrezza’s speed of delivery, rapid glucose control and rapid exit from the body. Oct. 4, 2017 1:49 p.m. ET MannKind (MNKD: Nasdaq) By Maxim Group ($2.20, Oct. 2, 2017) MannKind announced that the Food and Drug Administration has approved the label revision Afrezza, including for the first time since its 2014 approval demonstration of the “speed” at which Afrezza delivers insulin and manages blood sugar. Speed is key: The label now includes the differentiated pharmacokinetic/pharmacodynamic (PK/PD) profile for Afrezza demonstrating linear kinetics. Both the 4-unit and 12-unit doses appear in the blood in one minute and reach effective (effects on insulin) levels in 12 minutes. Peak effects are reached at 35 minutes for 4 units and 45 minutes for 12 units with the 4-unit and 12-unit returning to baseline after 90 minutes and 180 minutes, respectively. The rapid action and exit should help patients not only better control mealtime sugar levels but also overnight hyperglycemia or Hypoglycemia. [We rate MannKind at Buy with a $4 price target.] Dosing and learning to titrate: For any insulin product, learning to manage the disease and learning about insulin use is key to effective management. The updated label includes an additional step to mealtime dose adjust with Afrezza as individual patients will have different insulin needs. Another step in the restructuring process too: MannKind also announced a warrant exchange (to be completed Oct 3, 2017), exchanging series A and series B warrants that contained reset provisions and limited the amount of capital the company could raise to $10 million. With the warrants off the table (for 1.3 million common shares), the company will have 22 million available shares and can raise as much as $50 million through its at-the-market (ATM) [stock offerings] as it continues to undergo capital restructuring. Conclusion: The label revision is a victory for MannKind as the relaunch of Afrezza continues to build traction. With label claims highlighting Afrezza’s speed of delivery, rapid glucose control and rapid exit from the body, the 100-plus dedicated reps now have a new tool to engage and educate doctors and patients which should help drive adoption. Debt obligations for MannKind ($167 million) consist of $28 million in convertible notes, $60 million in facility financing and $80 million held by the Mann Group. The convertible notes at 5.75% interest are due in 2018. The facility financing obligation(s) of $60 million is secured with assets including intellectual property (IP) and the Danbury, Conn., facility. $45 million at 9.75% interest is payable as follows: $10 million Oct. 31 and $15 million in each July 2018 and 2019. $5 million was converted to equity in June. $15 million of tranche B notes at 8.75% interest are due in $5 million installments each in May 2018 and 2019, and December 2019. On Sept. 29, MannKind completed a warrant exchange; all series A and series B warrants for 1.3 million shares of stock. The warrants contained reset provisions and limited the amount of capital that could be raised to $10 million. With the warrants exchanged, the company has 22 million shares available on the shelf and can raise up to $50 million through its ATM as it continues to work towards restructuring. So what’s next? MannKind will likely raise capital (debt and equity) but with: 1) a fundamental health-care group and the Mann Family as principal paper holders; 2) a state-of-the-art 260,000-plus square-foot manufacturing plant in Danbury; and 3) an inhalable insulin that could be disruptive to the diabetes market. -- Jason Kolbert -- Jason McCarthy
|
|
|
|
Post by lakers on Oct 6, 2017 10:12:29 GMT -5
The facility financing obligation(s) of $60 million is secured with assets including intellectual property (IP) and the Danbury, Conn., facility. $45 million at 9.75% interest is payable as follows: $10 million Oct. 31 and $15 million in each July 2018 and 2019. $5 million was converted to equity in June. $15 million of tranche B notes at 8.75% interest are due in $5 million installments each in May 2018 and 2019, and December 2019 So what’s next? MannKind will likely raise capital (debt and equity) but with: 1) a fundamental health-care group and the Mann Family as principal paper holders; 2) a state-of-the-art 260,000-plus square-foot manufacturing plant in Danbury; and 3) an inhalable insulin that could be disruptive to the diabetes market. Read more: mnkd.proboards.com/thread/887/analyst-comments-thread?page=43#ixzz4ujxHGTjkSo, $10M is due Deerfield on 10/31/17. Mnkd needs $90 to extend the runway for 9 months. Most likely, "a fundamental health-care group" will invest $100M in Mnkd for 10% stake for a valuation of $1 B. This will support Pps at $10/sh. This dovetails with Nate's Mnkd low-end valuation. The new label helps Mnkd negotiate from a position of strength! IMHO, Pps will find strong support at $10-$12. Remember Pps rebounded to $2.4 pre-split ($12 post-spit) when Sny returned A to Mnkd in Apr 2016. Rock sold around 10K share ~$2.3/sh pre-split for a big profit. He bought ~ 70 cents/sh upon Sny dumping A. Oct. 5 at 8:16 AM NatesNotes @vibes121 can't tell you about covering (don't know!); still believe "fair value" for $MNKD today is somewhere in the $1B-$3B range (never Oct. 5 at 8:16 AM NatesNotes @vibes121 mind looking out a few years to when Afrezza has captured more of the market) 3 3 Oct. 6 at 6:41 AM NatesNotes @jaguarjkd007 send me an email sometime this morning, Jag, and I'll send you the email I sent out last night for subscribers... Read more: mnkd.proboards.com/thread/8565/nate-on-stocktwits?page=3#ixzz4ujybTPPWIf that Health Care group is a major one like UHC, it will certainly cover A as Tier 1 in 2018. Big win for A. I forgot MC mentioned it as Anthem or Optum? Could someone remind me what new health care group signs up with Mnkd in Jan 2018? Most likely that one will invest in Mnkd TBA this Oct. More good news to come in 3 weeks: recap. A couple of international expansion would be great. BoD and MC are brilliant lately! |
|
|
|
Post by sportsrancho on Oct 6, 2017 10:36:06 GMT -5
The facility financing obligation(s) of $60 million is secured with assets including intellectual property (IP) and the Danbury, Conn., facility. $45 million at 9.75% interest is payable as follows: $10 million Oct. 31 and $15 million in each July 2018 and 2019. $5 million was converted to equity in June. $15 million of tranche B notes at 8.75% interest are due in $5 million installments each in May 2018 and 2019, and December 2019 So what’s next? MannKind will likely raise capital (debt and equity) but with: 1) a fundamental health-care group and the Mann Family as principal paper holders; 2) a state-of-the-art 260,000-plus square-foot manufacturing plant in Danbury; and 3) an inhalable insulin that could be disruptive to the diabetes market. Read more: mnkd.proboards.com/thread/887/analyst-comments-thread?page=43#ixzz4ujxHGTjkSo, $10M is due Deerfield on 10/31/17. Mnkd needs $90 to extend the runway for 9 months. Most likely, "a fundamental health-care group" will invest $100M in Mnkd for 10% stake for a valuation of $1 B. This will support Pps at $10/sh. This dovetails with Nate's Mnkd low-end valuation. The new label helps Mnkd negotiate from a position of strength! IMHO, Pps will find strong support at $10-$12. Remember Pps rebounded to $2.4 pre-split ($12 post-spit) when Sny returned A to Mnkd in Apr 2016. Rock sold around 10K share ~$2.3/sh pre-split for a big profit. He bought ~ 70 cents/sh upon Sny dumping A. Oct. 5 at 8:16 AM NatesNotes @vibes121 can't tell you about covering (don't know!); still believe "fair value" for $MNKD today is somewhere in the $1B-$3B range (never Oct. 5 at 8:16 AM NatesNotes @vibes121 mind looking out a few years to when Afrezza has captured more of the market) 3 3 Oct. 6 at 6:41 AM NatesNotes @jaguarjkd007 send me an email sometime this morning, Jag, and I'll send you the email I sent out last night for subscribers... Read more: mnkd.proboards.com/thread/8565/nate-on-stocktwits?page=3#ixzz4ujybTPPWIf that Health Care group is a major one like UHC, it will certainly cover A as Tier 1 in 2018. Big win for A. I forgot MC mentioned it as Anthem or Optum? Could someone remind me what new health care group signs up with Mnkd in Jan 2018? Most likely that one will invest in Mnkd TBA this Oct. More good news to come in 2 weeks: recap. A couple of international expansion would be great. BoD and MC are brilliant lately! . But number one, our sales force was hired in February. We started with a small beta sales force last year, and we subsequently expanded them to a full-time MannKind sales force in February. And we started, February with about 70 FTEs, we since hired some Medical Liaisons and we’ve got a fully integrated sales team, I think right about 90ish sales reps today, and our insurance coverage continues to expand, so we have Express Scripts with no prior authorization, Aetna, Anthem and more to come. Thank you Lakers, I don’t need to read another post all day:-)) |
|
|
|
Post by buyitonsale on Oct 6, 2017 10:41:40 GMT -5
IMO MNKD will never give away equity to anyone below 3B valuation.
Convertible debt is what I want to see. Better yet a foreign distribution deal with money upfront and wait for a few months to negotiate financing on better terms.
|
|
|
|
Post by therealisaching on Oct 6, 2017 10:43:33 GMT -5
While I think Mike will be laying down another card soon I'm not reading the same into that Barron's/Maxim comment.
So what’s next? MannKind will likely raise capital (debt and equity) but with: 1) a fundamental health-care group and the Mann Family as principal paper holders; 2) a state-of-the-art 260,000-plus square-foot manufacturing plant in Danbury; and 3) an inhalable insulin that could be disruptive to the diabetes market.
1 = Deerfield & Mann Family as principal paper holders
|
|
|
|
Post by patten1962 on Oct 6, 2017 11:11:27 GMT -5
The facility financing obligation(s) of $60 million is secured with assets including intellectual property (IP) and the Danbury, Conn., facility. $45 million at 9.75% interest is payable as follows: $10 million Oct. 31 and $15 million in each July 2018 and 2019. $5 million was converted to equity in June. $15 million of tranche B notes at 8.75% interest are due in $5 million installments each in May 2018 and 2019, and December 2019 So what’s next? MannKind will likely raise capital (debt and equity) but with: 1) a fundamental health-care group and the Mann Family as principal paper holders; 2) a state-of-the-art 260,000-plus square-foot manufacturing plant in Danbury; and 3) an inhalable insulin that could be disruptive to the diabetes market. Read more: mnkd.proboards.com/thread/887/analyst-comments-thread?page=43#ixzz4ujxHGTjkSo, $10M is due Deerfield on 10/31/17. Mnkd needs $90 to extend the runway for 9 months. Most likely, "a fundamental health-care group" will invest $100M in Mnkd for 10% stake for a valuation of $1 B. This will support Pps at $10/sh. This dovetails with Nate's Mnkd low-end valuation. The new label helps Mnkd negotiate from a position of strength! IMHO, Pps will find strong support at $10-$12. Remember Pps rebounded to $2.4 pre-split ($12 post-spit) when Sny returned A to Mnkd in Apr 2016. Rock sold around 10K share ~$2.3/sh pre-split for a big profit. He bought ~ 70 cents/sh upon Sny dumping A. Oct. 5 at 8:16 AM NatesNotes @vibes121 can't tell you about covering (don't know!); still believe "fair value" for $MNKD today is somewhere in the $1B-$3B range (never Oct. 5 at 8:16 AM NatesNotes @vibes121 mind looking out a few years to when Afrezza has captured more of the market) 3 3 Oct. 6 at 6:41 AM NatesNotes @jaguarjkd007 send me an email sometime this morning, Jag, and I'll send you the email I sent out last night for subscribers... Read more: mnkd.proboards.com/thread/8565/nate-on-stocktwits?page=3#ixzz4ujybTPPWIf that Health Care group is a major one like UHC, it will certainly cover A as Tier 1 in 2018. Big win for A. I forgot MC mentioned it as Anthem or Optum? Could someone remind me what new health care group signs up with Mnkd in Jan 2018? Most likely that one will invest in Mnkd TBA this Oct. More good news to come in 3 weeks: recap. A couple of international expansion would be great. BoD and MC are brilliant lately! Great post! Thank you for all you do! |
|
|
|
Post by patten1962 on Oct 6, 2017 11:13:13 GMT -5
The facility financing obligation(s) of $60 million is secured with assets including intellectual property (IP) and the Danbury, Conn., facility. $45 million at 9.75% interest is payable as follows: $10 million Oct. 31 and $15 million in each July 2018 and 2019. $5 million was converted to equity in June. $15 million of tranche B notes at 8.75% interest are due in $5 million installments each in May 2018 and 2019, and December 2019 So what’s next? MannKind will likely raise capital (debt and equity) but with: 1) a fundamental health-care group and the Mann Family as principal paper holders; 2) a state-of-the-art 260,000-plus square-foot manufacturing plant in Danbury; and 3) an inhalable insulin that could be disruptive to the diabetes market. Read more: mnkd.proboards.com/thread/887/analyst-comments-thread?page=43#ixzz4ujxHGTjkSo, $10M is due Deerfield on 10/31/17. Mnkd needs $90 to extend the runway for 9 months. Most likely, "a fundamental health-care group" will invest $100M in Mnkd for 10% stake for a valuation of $1 B. This will support Pps at $10/sh. This dovetails with Nate's Mnkd low-end valuation. The new label helps Mnkd negotiate from a position of strength! IMHO, Pps will find strong support at $10-$12. Remember Pps rebounded to $2.4 pre-split ($12 post-spit) when Sny returned A to Mnkd in Apr 2016. Rock sold around 10K share ~$2.3/sh pre-split for a big profit. He bought ~ 70 cents/sh upon Sny dumping A. Oct. 5 at 8:16 AM NatesNotes @vibes121 can't tell you about covering (don't know!); still believe "fair value" for $MNKD today is somewhere in the $1B-$3B range (never Oct. 5 at 8:16 AM NatesNotes @vibes121 mind looking out a few years to when Afrezza has captured more of the market) 3 3 Oct. 6 at 6:41 AM NatesNotes @jaguarjkd007 send me an email sometime this morning, Jag, and I'll send you the email I sent out last night for subscribers... Read more: mnkd.proboards.com/thread/8565/nate-on-stocktwits?page=3#ixzz4ujybTPPWIf that Health Care group is a major one like UHC, it will certainly cover A as Tier 1 in 2018. Big win for A. I forgot MC mentioned it as Anthem or Optum? Could someone remind me what new health care group signs up with Mnkd in Jan 2018? Most likely that one will invest in Mnkd TBA this Oct. More good news to come in 2 weeks: recap. A couple of international expansion would be great. BoD and MC are brilliant lately! . But number one, our sales force was hired in February. We started with a small beta sales force last year, and we subsequently expanded them to a full-time MannKind sales force in February. And we started, February with about 70 FTEs, we since hired some Medical Liaisons and we’ve got a fully integrated sales team, I think right about 90ish sales reps today, and our insurance coverage continues to expand, so we have Express Scripts with no prior authorization, Aetna, Anthem and more to come. Thank you Lakers, I don’t need to read another post all day:-)) I would like to read a post where we close over $8! Lmfao |
|
|
|
Post by gamblerjag on Oct 6, 2017 11:24:55 GMT -5
. But number one, our sales force was hired in February. We started with a small beta sales force last year, and we subsequently expanded them to a full-time MannKind sales force in February. And we started, February with about 70 FTEs, we since hired some Medical Liaisons and we’ve got a fully integrated sales team, I think right about 90ish sales reps today, and our insurance coverage continues to expand, so we have Express Scripts with no prior authorization, Aetna, Anthem and more to come. Thank you Lakers, I don’t need to read another post all day:-)) I would like to read a post where we close over $8! Lmfao [br We close above $8😎 |
|
|
|
Post by lakers on Oct 6, 2017 11:49:06 GMT -5
Right on cue. It's not a coordinated pump, folks! Mnkd deserves $1B-$3B today according to Nate! MannKind (MNKD) PT Raised to $7 at Maxim Group October 6, 2017 12:04 PM Maxim likes MannKind, sees 33% upside Oct. 6, 2017 12:31 PM • SA Editor Douglas W. House Citing lower risk in AFREZZA's relaunch due to the recent labeling revision, Maxim Group ups its price target on MannKind (MNKD +6%) to $7 (33% upside) from $4, not unexpected since shares are currently exchanging hands at ~$5.25.Source: Bloomberg Read more: mnkd.proboards.com/thread/8794/maxim-raised-mnkd-7#ixzz4ukP0bDqH |
|
|
|
Post by dreamboatcruise on Oct 6, 2017 13:43:52 GMT -5
I would like to read a post where we close over $8! Lmfao [br We close above $8😎 I love good fiction. Some of my favorite authors in that genre write here  |
|
|
|
Post by lsl428 on Oct 6, 2017 14:06:57 GMT -5
While I think Mike will be laying down another card soon I'm not reading the same into that Barron's/Maxim comment. So what’s next? MannKind will likely raise capital (debt and equity) but with: 1) a fundamental health-care group and the Mann Family as principal paper holders; 2) a state-of-the-art 260,000-plus square-foot manufacturing plant in Danbury; and 3) an inhalable insulin that could be disruptive to the diabetes market. 1 = Deerfield & Mann Family as principal paper holders My take is a fundamental health care group is Deerfield actually |
|
|
|
Post by dreamboatcruise on Oct 6, 2017 15:25:27 GMT -5
While I think Mike will be laying down another card soon I'm not reading the same into that Barron's/Maxim comment. So what’s next? MannKind will likely raise capital (debt and equity) but with: 1) a fundamental health-care group and the Mann Family as principal paper holders; 2) a state-of-the-art 260,000-plus square-foot manufacturing plant in Danbury; and 3) an inhalable insulin that could be disruptive to the diabetes market. 1 = Deerfield & Mann Family as principal paper holders My take is a fundamental health care group is Deerfield actually So are you saying that Maxim is merely rehashing known facts in a clever bid to make it sound interesting... i.e. Mann entities and Deerfield do indeed already hold debt, MNKD does own a factory (though unclear how that can be used for additional financing since it is collateral for previously obtained financing), and (the big surprise) MNKD has an inhalable insulin? To me it seems unlikely the Mann family has enough money to be meaningful in helping to recapitalize MNKD... or if they did why have they sat on the sidelines so long. I'm keeping a pretty skeptical stance on Maxim. I think it is pretty clear that they are looking to influence share price rather than merely giving unbiased analysis. It's still positive that Maxim is covering MNKD as I would suspect that they are associated with some monied entities that are/were buying shares. But, unless one believes someone within MNKD is leaking information to Maxim (illegally), their speculation should be taken with grain of salt. |
|
